INmune Short Term Debt vs Net Debt Analysis
INMB Stock | USD 11.29 0.45 4.15% |
INmune Bio financial indicator trend analysis is infinitely more than just investigating INmune Bio recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether INmune Bio is a good investment. Please check the relationship between INmune Bio Short Term Debt and its Net Debt accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.
Short Term Debt vs Net Debt
Short Term Debt vs Net Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of INmune Bio Short Term Debt account and Net Debt. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between INmune Bio's Short Term Debt and Net Debt is -0.42. Overlapping area represents the amount of variation of Short Term Debt that can explain the historical movement of Net Debt in the same time period over historical financial statements of INmune Bio, assuming nothing else is changed. The correlation between historical values of INmune Bio's Short Term Debt and Net Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Term Debt of INmune Bio are associated (or correlated) with its Net Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Debt has no effect on the direction of Short Term Debt i.e., INmune Bio's Short Term Debt and Net Debt go up and down completely randomly.
Correlation Coefficient | -0.42 |
Relationship Direction | Negative |
Relationship Strength | Very Weak |
Short Term Debt
Net Debt
The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.Most indicators from INmune Bio's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into INmune Bio current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.The current year's Enterprise Value is expected to grow to about 185.9 M, whereas Selling General Administrative is forecasted to decline to about 6.4 M.
2010 | 2023 | 2024 (projected) | Interest Income | 77.7K | 69.9K | 62.2K | Net Interest Income | 77.7K | 69.9K | 62.2K |
INmune Bio fundamental ratios Correlations
Click cells to compare fundamentals
INmune Bio Account Relationship Matchups
High Positive Relationship
High Negative Relationship
INmune Bio fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 24.5M | 40.7M | 99.9M | 81.8M | 57.0M | 41.6M | |
Total Current Liabilities | 700.4K | 1.8M | 4.4M | 10.9M | 18.5M | 19.4M | |
Total Stockholder Equity | 23.6M | 38.8M | 80.2M | 60.1M | 38.1M | 33.6M | |
Net Tangible Assets | 7.1M | 22.2M | 63.7M | 43.6M | 50.1M | 52.6M | |
Retained Earnings | (21.3M) | (33.4M) | (63.7M) | (91.0M) | (121.0M) | (115.0M) | |
Accounts Payable | 692.1K | 1.6M | 3.8M | 5.2M | 7.9M | 8.3M | |
Cash | 7.0M | 22.0M | 74.8M | 52.2M | 35.8M | 23.6M | |
Cash And Short Term Investments | 7.0M | 22.0M | 74.8M | 52.2M | 35.8M | 23.6M | |
Capital Surpluse | 44.8M | 72.1M | 143.9M | 151.8M | 174.6M | 183.3M | |
Total Liab | 860.5K | 1.9M | 19.7M | 21.7M | 18.9M | 19.8M | |
Total Current Assets | 7.8M | 24.0M | 82.6M | 64.7M | 39.9M | 27.2M | |
Common Stock | 8.7K | 10.8K | 13.5K | 18K | 817K | 857.9K | |
Net Debt | (6.8M) | (21.8M) | (59.6M) | (36.8M) | (25.4M) | (26.7M) | |
Non Current Assets Total | 16.7M | 16.7M | 17.3M | 17.1M | 17.1M | 16.2M | |
Net Receivables | 645.4K | 1.8M | 5.5M | 8.5M | 2.4M | 2.8M | |
Common Stock Total Equity | 8.7K | 10.8K | 13.5K | 18K | 20.7K | 12.9K | |
Common Stock Shares Outstanding | 10.3M | 12.0M | 16.1M | 17.9M | 18.0M | 14.8M | |
Liabilities And Stockholders Equity | 24.5M | 40.7M | 99.9M | 81.8M | 57.0M | 46.8M | |
Non Current Liabilities Total | 160.2K | 126.3K | 15.4M | 10.8M | 397.0K | 377.1K | |
Other Current Assets | 769.3M | 2.0B | 7.8M | 4.0M | 1.7M | 1.6M | |
Other Stockholder Equity | 44.9M | 72.1M | 143.9M | 151.8M | 158.3M | 85.3M | |
Accumulated Other Comprehensive Income | (8.5K) | 10.7K | 1K | (699K) | (799K) | (759.1K) | |
Net Invested Capital | 23.6M | 38.8M | 94.7M | 74.8M | 48.1M | 49.4M | |
Net Working Capital | 7.1M | 22.2M | 78.2M | 53.8M | 21.5M | 29.0M | |
Retained Earnings Total Equity | (21.3M) | (33.4M) | (63.7M) | (91.0M) | (81.9M) | (77.8M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Complementary Tools for INmune Stock analysis
When running INmune Bio's price analysis, check to measure INmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy INmune Bio is operating at the current time. Most of INmune Bio's value examination focuses on studying past and present price action to predict the probability of INmune Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move INmune Bio's price. Additionally, you may evaluate how the addition of INmune Bio to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |
Is INmune Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. If investors know INmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about INmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.67) | Revenue Per Share 0.009 | Quarterly Revenue Growth (0.71) | Return On Assets (0.27) | Return On Equity (0.61) |
The market value of INmune Bio is measured differently than its book value, which is the value of INmune that is recorded on the company's balance sheet. Investors also form their own opinion of INmune Bio's value that differs from its market value or its book value, called intrinsic value, which is INmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because INmune Bio's market value can be influenced by many factors that don't directly affect INmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.